Axial involvement in patients with psoriatic arthritis (PsA) remains common and can be defined in terms of spinal disease alone or in combination with peripheral manifestations. Diagnosis is based upon inflammatory spinal symptoms or the presence of radiological sacroiliitis and other radiographic signs of spondylitis, or by criteria for axial Spondylarthritis (SpA) defined by AS AS (Assessment of SpondyloArthritis International Society). Although recent data are scarce for efficacy of traditional therapies for axial disease (e.g., nonsteroidal antiinflammatory drugs, methotrexate, etc.), limited data are available for targeted biologies and novel agents. We identify and evaluate the efficacy of therapeutic interventions for treatment of axial disease in PsA. This review is an update of the axial PsA section of the treatment recommendations project by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Updated guidelines for the management of axial disease in psoriatic arthritis

CAULI, ALBERTO;
2014

Abstract

Axial involvement in patients with psoriatic arthritis (PsA) remains common and can be defined in terms of spinal disease alone or in combination with peripheral manifestations. Diagnosis is based upon inflammatory spinal symptoms or the presence of radiological sacroiliitis and other radiographic signs of spondylitis, or by criteria for axial Spondylarthritis (SpA) defined by AS AS (Assessment of SpondyloArthritis International Society). Although recent data are scarce for efficacy of traditional therapies for axial disease (e.g., nonsteroidal antiinflammatory drugs, methotrexate, etc.), limited data are available for targeted biologies and novel agents. We identify and evaluate the efficacy of therapeutic interventions for treatment of axial disease in PsA. This review is an update of the axial PsA section of the treatment recommendations project by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
Axial; Psoriatic arthritis; Spondyloarthritis; Therapy; Anti-inflammatory agents, non-steroidal; Antirheumatic agents; Arthritis, Psoriatic; Axis, cervical vertebra; Biological products; Clinical trials, phase III as topic; Female; Humans; Male; Prognosis; Randomized controlled trials as topic; Risk assessment; Societies, medical; Treatment outcome; Practice guidelines as topic; Rheumatology; Immunology; Immunology and allergy
File in questo prodotto:
File Dimensione Formato  
CAULI PDF .pdf

non disponibili

Tipologia: versione editoriale
Dimensione 89.57 kB
Formato Adobe PDF
89.57 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11584/137079
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 27
social impact